Atlas Trials

Juventas Cell Therapy Ltd.

15 clinical trials · Sponsor

Sort:Newest firstOldest first

◉ Watch Juventas Cell Therapy Ltd.

RecordFirmDate
HY001N for Patients With Autoimmune Hemolytic Anemia After Failure ≥3 Lines of Therapy. (NCT07748533)Juventas Cell Therapy Ltd.2026-07-02
A Study of HY001N in the Treatment of Relapsed or Refractory Neurological Autoimmune Diseases (NCT07265206)Juventas Cell Therapy Ltd.2025-12-30
Inaticabtagene Autoleucel Injection in the Treatment of Autoimmune Hemolytic Anemia After Three or More Lines of Therapy (NCT07091370)Juventas Cell Therapy Ltd.2025-12-27
Clinical Trial of HY004 Cell Injection in the Treatment of Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma (NCT06005649)Juventas Cell Therapy Ltd.2025-09-01
A Study of HY004 Treatment in Adult Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia (r/r B-ALL) (NCT06009107)Juventas Cell Therapy Ltd.2025-06-30
A Study of CNCT19 in the Treatment of Relapsed or Refractory Neurological Autoimmune Diseases (NCT07275736)Juventas Cell Therapy Ltd.2025-03-01
Inaticabtagene Autoleucel Injection in the Treatment of Refractory Systemic Lupus Erythematosus-related Immune Thrombocytopenia (NCT06826430)Juventas Cell Therapy Ltd.2025-03-01
Inaticabtagene Autoleucel Injection Treatment for Adult Relapsed or Refractory Acute Lymphocytic Leukemia (NCT06450067)Juventas Cell Therapy Ltd.2024-06-05
Long-term Observational Study of Patients Treated With Inaticabtagene Autoleucel Injection (NCT06461351)Juventas Cell Therapy Ltd.2024-03-30
A Study of CNCT19 Treatment in Children and Adolescent r/r ALL Patients(Pediatric) (NCT05667506)Juventas Cell Therapy Ltd.2023-02-07
Exploratory Clinical Study of CNCT19 Anti CD19 Cell Therapy in the Treatment of Refractory Autoimmune Diseases (NCT06316791)Juventas Cell Therapy Ltd.2021-12-14
Clinical Trial of CNCT19 Cell Injection in the Treatment of Relapsed or Refractory Acute Lymphoblastic Leukemia (NCT04684147)Juventas Cell Therapy Ltd.2020-12-24
Phase II Clinical Trial of CNCT19 Cell Injection in the Treatment of Relapsed or Refractory Non-Hodgkin's Lymphoma (NCT04586478)Juventas Cell Therapy Ltd.2020-10-26
A Clinical Trial of CNCT19 Cells in the Treatment of CD19 Positive Relapsed or Refractory Acute Lymphoblastic Leukemia (NCT04230473)Juventas Cell Therapy Ltd.2020-03-13
A Clinical Trial of CNCT19 Cells in the Treatment of CD19 Positive Relapsed or Refractory Diffuse Non-Hodgkin Lymphoma (NCT04232826)Juventas Cell Therapy Ltd.2020-01-15

Track Juventas Cell Therapy Ltd. automatically

Every clearance here is in the API, with alerts when new ones post.